Possible scenario
Guidance Drives Re-Rating
20% Chance
The market focuses more on the profit-guidance increase than the spinoff signal. Strength in pharmaceuticals, cardiovascular devices after Shockwave Medical, and operating discipline lead investors to price J&J as a steadier compounder.
Secondary impacts
- Healthcare +0.3%
Tickers
- JNJ+3.4%
- MDT+0.4%
- ABT+0.3%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.